Fundraising Fox
/Companies
Sign in

Mitokinin

New York, US · Founded 2017 · 3 known investors

Find your way into Mitokinin

Sign up to find every way you can get introduced to Mitokinin

  • Your email: who you already know at Mitokinin, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Mitokinin team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Targeting mitochondria for neurodegenerative disease therapies.

Biotech

Founders & leadership

Mitokinin was founded in 2017 by Nicholas Hertz.

NHNicholas Hertz
Nicholas HertzFounder
DC
Doug CrawfordNamed on SEC filing
DD
Daniel de Roulet, Jr.Named on SEC filing

Board

JF
Johannes FruehaufBoard director

Investors · 3

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · board seat on SEC Form D · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$9.5M disclosed across 2 rounds · 2017–2018

▶$5MraisedNov 2018 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas CrawfordDirector
  • Peter ParkerDirector
  • Nicholas HertzDirector
  • Daniel de Roulet, Jr.Executive Officer, Director
Offering amount
$6M
Amount sold
$5M
First sale
Oct 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedSep 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Doug CrawfordDirector
  • Nicholas HertzDirector
  • Daniel de Roulet, Jr.Executive Officer, Director
  • Johannes FruehaufDirector
Offering amount
$4.5M
Amount sold
$4.5M
First sale
Sep 2017
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Discovering Biotech Startups: A map for Selling to Mitokininblog.zymewire.com · Feb 2020

Frequently asked questions

What does Mitokinin do?
Targeting mitochondria for neurodegenerative disease therapies.
Who founded Mitokinin?
Mitokinin was founded by Nicholas Hertz in 2017.
Who are Mitokinin's investors?
Mitokinin's investors include Mission Bay Capital, Mission Biocapital, Pfizer Venture Investments.
How much funding has Mitokinin raised?
Mitokinin has disclosed $9.5M raised across 2 rounds.
Where is Mitokinin headquartered?
Mitokinin is headquartered in New York, US.